Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 - - Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the ...

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery  Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (US ...

Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medicationStudy outcomes support plans for further international expansion HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeutics Ltd. ( ...

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Altamira Therapeutics Ltd. (NASDAQ:CYTO). The in-depth 28-page initiation report includes detailed information on the Altamira Therapeutic's business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include:    Altamira's Delivery Platforms to Pote ...

24,277 15,395 984,191 Confidential 18 • sale of equity or convertible debt securities altamira therapeutics Business Update & Full Year 2023 Earnings Call April 10, 2024 • Thomas Meyer, Ph.D. • Covadonga Pañeda, Ph.D. NASDAQ: CYTO Forward-Looking Statements Update NASDAQ: CYTO Transitioning to Become a Focused RNA Delivery Company • Substantially reduced operating expenses / cash burn 5 6 • Insertion of peptide into adeno-associated virus (AAV) vectors significantly enhances cell transduction 'Picks and Sho ...

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Conference Call April 10, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Operator Good morning, and welcome to the Altamira Therapeutics Business Update and Full Year 2023 Earnings Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and the Chief Executive Officer, and Covadonga Pañeda, Altamira's Chief Operating Officer. Earlier to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ OR ☐ SHELL COMPANY REPORT PURSUANT T ...

Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering of legacy assets underway as Company transitions to focused RNA delivery technology providerAchieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debtFinished year with shareholders' equity of CHF 6.5 million, improved by CHF 14.8 million   HAMILTON, BERMUDA -- April ...

Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from i ...

HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira's peptide-based delivery technology      Increased potency may help to reduce AAV immunogenicity and resistance to AAVs in certain cell types  HAMILTON, BERMUDA, Feb. 7, 2024 -- Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based te ...